Skip to main content
SpringerLink
Log in

Erstes Antikörper-Wirkstoff-Konjugat zur Therapie des Mammakarzinoms

  • Pharmaforum
  • Published:
gynäkologie + geburtshilfe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Pressekonferenz „Innovatives Wirkprinzip für mehr Perspektiven — Zulassung für Kadcyla® beim HER2-positiven metastasierten Mammakarzinom“, München, 6. Dezember 2013, Veranstalter: Roche

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Christine Cramer

Authors
  1. Christine Cramer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cramer, C. Erstes Antikörper-Wirkstoff-Konjugat zur Therapie des Mammakarzinoms. gynäkologie + geburtshilfe 19, 64 (2014). https://doi.org/10.1007/s15013-014-0362-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15013-014-0362-7

Search

Navigation